Objectives: To identify patients' beliefs or behaviors related to treatment adherence and to assess association between asthma control and adherence in Asian patients with asthma. Methods: We conducted a cross-sectional observational study of adult patients with asthma from specialist clinics in six Asian countries. Patients who were deemed by their treating physicians to require a maintenance treatment with an inhaler for at least 1 year were recruited. Patients completed a 12-item questionnaire related to health beliefs and behaviors, the 8-item Morisky Medication Adherence Scale (MMAS-8), the Asthma Control Test (ACT™), and the Standardized Asthma Quality of Life Questionnaire (AQLQ-S). Results: Of the 1054 patients recruited, 99% were current users of inhaled corticosteroids. The mean ACT score was 20.0 ± 4.5 and 64% had well-controlled asthma. The mean MMAS-8 score was 5.5 ± 2.0 and 53% were adherent. Adherence was significantly associated with patients' understanding of the disease and inhaler techniques, and with patients' acceptance of inhaler medicines in terms of benefits, safety, convenience, and cost (p < 0.01 for all). In multivariate analysis, three questions related to patients' acceptance of inhaler medicines remained significantly associated with poor adherence, after adjusting for potential confounders: "I am not sure inhaler type medicines work well" (p = 0.001), "Taking medicines more than once a day is inconvenient" (p = 0.002), and "Sometimes I skip my inhaler to use it over a longer period" (p < 0.001). Conclusions: Our study showed that patients' acceptance of the benefits, convenience and cost of inhaler medications have a significant impact on treatment adherence in the participating Asian countries.
Bibliographical noteFunding Information:
Dr. W. Boonsawat has received speaker’s honoraria from AstraZeneca, GlaxoSmithKline, MSD, Nycomed, Otsuka, and Boehringer Ingelheim. Dr. V. N. Nguyen has received speaker’s honoraria and research funds from GlaxoSmithKline, AstraZeneca, Sanofi Aventis and Pfizer. Dr. C. Wang has received honoraria for consulting and presentation, and research funds from GlaxoSmithKline, AstraZeneca and Boehringer Ingelheim. Dr. N. Kwon is an employee of GlaxoSmithKline and owns stocks in GlaxoSmithKline. The other authors declare they have no competing interests. The study was funded by GlaxoSmithKline. Statistical support was provided by Dr Liang Shen and editorial support by Hui Hwa Choo of Research2Trials Clinical Solutions Pte Ltd and was funded by GlaxoSmithKline.
- Asthma control
- Inhaled corticosteroids